Shortwave Life Sciences PLC – London-based drug development for mental health, formerly called Psych Capital – Announces it has achieved “positive” safety results from latest pre-clinical pharmacodynamics study, which was intended to demonstrate the safety of its proprietary psilocybin-based drug combination at elevated doses to treat anorexia. The study tested the safety of buccal administration of Shortwave’s combination drug. Results in rats tested showed no adverse effects, weight changes or behavioural changes following the psychedelic effects. The company begins to gear up for human trials.

Chief Executive Officer Rivki Stern Youdkevich says: “This is a monumental step forward for Shortwave. Our relentless pursuit of breakthrough mental health treatments comes with the responsibility of ensuring safety at every stage. We are proud of the positive outcomes from this rigorous pre-clinical trial, further validating our patent-pending drug combination and buccal delivery system. With this success, we are reaffirmed in our approach to addressing the global mental health crisis.”

Current stock price: untraded at 0.45 pence per share on the Aquis Exchange in London on Thursday afternoon.

Original Source